[18F]F-氟昔洛韦正电子发射断层显像/计算机断层显像在根治性膀胱切除术前对肌层浸润性膀胱癌分期的初步研究
这项单中心前瞻性初步研究纳入16例CT/MRI诊断为T2-T4、N0的肌层浸润性膀胱癌患者,在根治性膀胱切除术前进行[18F]F-氟昔洛韦PET/CT,并与病理对照。结果显示淋巴结转移检测特异度高(总体0.91,95%CI 0.81-1.00),但灵敏度低(总体0.13,95%CI 0-0.44);原发肿瘤灵敏度0.89(95%CI 0.78-1.00)。动力学参数k1和vb可区分低危(pT0-pT1)与高危(pT2-pT4)病变(p<0.05)。
要点
- 淋巴结转移检测总体特异度0.91(95%CI 0.81-1.00),总体灵敏度0.13(95%CI 0-0.44)。
- 原发肿瘤检测总体灵敏度0.89(95%CI 0.78-1.00),特异度0.39(95%CI 0.33-0.50)。
- 动力学参数k1和vb可区分低危(pT0-pT1)与高危(pT2-pT4)原发膀胱病变(p<0.05)。
核心结论
- [18F]F-氟昔洛韦对肌层浸润性膀胱癌分期显示良好特异度和与病理的一致率,灵敏度与CT/MRI相仿。
- 动力学参数k1能够 delineate 更高分期(≥pT2)的原发病灶。
- 不同病灶间可见氨基酸转运体表达异质性。
- 需要进一步研究以理解[18F]F-氟昔洛韦PET/CT在该疾病中与其他影像模态的关系。
研究设计与样本
- 单中心前瞻性初步研究,纳入CT/MRI诊断为T2-T4、N0且计划行根治性膀胱切除术的肌层浸润性膀胱癌患者。
- 采集动态和静态[18F]F-氟昔洛韦PET/CT图像,临床阅片者评估原发膀胱病灶确认和盆腔淋巴结转移,并与根治性膀胱切除术病理对照。
- 共纳入16例患者(中位年龄73岁,范围57-88岁,11例男性,5例女性),其中12例在根治性膀胱切除术前接受新辅助化疗。
主要发现
- 所有三位阅片者检测淋巴结转移的总体特异度为0.91(95%CI 0.81-1.00),与病理总体一致率为0.67(95%CI 0.44-0.83)。
- 所有阅片者识别淋巴结阳性疾病的总体PPV为0.4(95%CI 0-1.00),总体灵敏度为0.13(95%CI 0-0.44)。
- 检测原发肿瘤的总体PPV为0.69(95%CI 0.47-0.88),灵敏度为0.89(95%CI 0.78-1.00),NPV为0.70(95%CI 0.33-1.00),特异度为0.39(95%CI 0.33-0.50)。
- 原发膀胱肿瘤的房室分析显示,k1和vb参数可显著区分低危(pT0-pT1)与高危(pT2-pT4)疾病(p<0.05)。
- 免疫组化评估显示肿瘤[18F]F-氟昔洛韦摄取及动力学参数与氨基酸转运体表达无显著相关性。
关键数值与推荐
- 淋巴结转移检测:总体特异度0.91(95%CI 0.81-1.00),总体灵敏度0.13(95%CI 0-0.44),总体PPV 0.4(95%CI 0-1.00),与病理总体一致率0.67(95%CI 0.44-0.83)。
- 原发肿瘤检测:总体灵敏度0.89(95%CI 0.78-1.00),总体PPV 0.69(95%CI 0.47-0.88),NPV 0.70(95%CI 0.33-1.00),特异度0.39(95%CI 0.33-0.50)。
- 动力学参数k1和vb在低危(pT0-pT1)与高危(pT2-pT4)原发膀胱病变间差异有统计学意义(p<0.05)。
局限性
- 原文结论指出需要进一步研究以理解[18F]F-氟昔洛韦PET/CT在该疾病中与其他影像模态的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess the ability of [18F]F-fluciclovine-PET/CT to stage muscle invasive bladder cancer (MIBC) before radical cystectomy. METHODS: This single-site prospective pilot study enrolled patients with MIBC and T2-T4, N0 disease on CT/MRI slated to undergo radical cystectomy (RC). Dynamic and static [18F]F-fluciclovine-PET/CT images were acquired. Clinical readers assessed for confirmation of the primary bladder lesion on imaging and the presence of pelvic nodal metastases. Findings were compared to pathology at RC. Kinetic parameters from dynamic PET/CT were compared across bladder lesions of different clinical stages. RESULTS: The study enrolled sixteen patients (median age: 73 years, range: 57-88 years, 11 males, 5 females), twelve receiving neoadjuvant chemotherapy before RC. There was high specificity amongst all three readers for detecting lymph node metastases (overall specificity: 0.91, 95%CI: 0.81-1.00) with good overall agreement rate with pathology (0.67, 95%CI: 0.44-0.83). The overall PPV for all readers for identifying node-positive disease was 0.4 (95%CI: 0-1.00), and the overall sensitivity was 0.13 (95%CI: 0-0.44). The overall PPV for detecting the primary tumor was 0.69 (95%CI: 0.47-0.88), and the sensitivity was 0.89 (95%CI: 0.78-1.00), with NPV and specificity being 0.70 (95%CI: 0.33, 1.00) and 0.39 (95%CI: 0.33, 0.50), respectively. Compartmental analysis of the primary bladder tumor revealed that k1 and vb parameters significantly differentiated between low (pT0-pT1) and high (pT2-pT4) risk disease (p < 0.05). Immunohistochemical assessment showed no significant correlation of tumor [18F]F-fluciclovine uptake nor kinetic parameter with amino acid transporter expression. CONCLUSIONS: [18F]F-fluciclovine demonstrates good specificity and agreement rate for MIBC staging, with sensitivity like CT/MRI. Kinetic parameters such as k1 was able to delineate higher-stage ( ≥ = pT2) primary lesions. Heterogeneous amino acid transporter expression can be seen across lesions. Further studies are warranted to understand [18F]F-fluciclovine PET/CT use in the context of other imaging modalities in this disease. CLINICAL TRIAL REGISTRATION: NCT04018053 Registered 2/26/2020.
引用
- Ng TSC, Liu M, Robertson M, et al. A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy. Eur J Nucl Med Mol Imaging. 2025. PMID: 40257614. doi:10.1007/s00259-025-07287-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。